Impact BioMedical Scientific Partner GRDG Sciences to be

Impact BioMedical is a wholly owned subsidiary of DSS

“A Real-Life Mission Impossible” — Global Research and Discovery Group steps in the spotlight for documentary, “The BioQuest” — Filming to start December 3

ROCHESTER, NY, Oct. 19, 2022 (GLOBE NEWSWIRE) — Daryl Thompson, founder of GRDG Sciences LLC (“GRDG”) in Winter Haven, Florida, has spent a career working just out of the spotlight and inventing biological and medical technologies that, when fully deployed, could better the lives of people around the world.

But all that may change as GRDGa scientific research partner of Impact BioMedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), announced today that it will be the subject of a documentary film highlighting the passion, the search, and the cutting-edge discoveries that push the company — and its founder — behind a single-minded goal: creating a healthier world quickly and naturally.

“We are thrilled to take the audience behind the scenes and around the world to discover solutions to problems that have plagued humanity for thousands of years,” said Thompson. “From the Florida Everglades to the rainforests of South America to the jungles of Africa and beyond, we’re going to show everyone what we do and how we do it.”

The documentary project comes on the heels of GRDG’s completion of Sombrero, a five-year multi-pronged project that yielded multiple patents and potentially billions of dollars in licensing opportunities. But it also paved the way for something deeper.

“Sombrero allowed us to make discoveries, for sure, but it also allowed us to create a template for problem solving that I think can be duplicated around the world,” said Thompson. “That is part of what the film is about, the blueprint to forming several quick-thinking, fast-acting groups around the world that can identify potential problems and create solutions outside the traditional channels that aren’t able to move as fast.”

For GRDG, that team included a Washington insider, an investor, and a lab.

A Real-Life Mr. Phelps
For Dr. Roscoe Moore, retired United States Assistant Surgeon General and former Epidemic Intelligence Services Officer at the US Centers for Disease Control, meeting Thompson and understanding his approach led to a creative partnership.

“Daryl came to me about six years ago, and we met a couple times, and lo and beyond, I became an advisor,” said Dr. Moore. “I don’t endorse any specific product — I never have; but I just look at the science and the science says that what he’s doing works.”

Moore, who is now GRDG’s Chief Scientific Advisor, said that Thompson’s model of getting things done is something that is vital in this day and age.

“The NIH model is great for research, but it takes a long time to get anything done,” he said. “Big government operations are not meant to be stealth. We needed someone to get things done in a way that cuts through the red tape without cutting corners. In that regard, Daryl’s efforts have been stellar.”

For Thompson, Moore is more than just an advisor.

“Roscoe is our Mr. Phelps,” said Thompson, referring to the director of the Impossible Mission Force. “He would tell us about several different directions and problems that needed solving and then gave us the freedom to choose which one to solve.”

That partnership led GRDG to discover several breakthrough technologies that could tackle unmet global problems, including:

  • Linebacker: Multi-faceted therapeutic platform for metabolic, neurologic, cancer, and infectious diseases created to mirror the Panacea Project, a US Defense Advanced Research Projects Agency (DARPA) program to provide novel, multi-target therapeutics for unmet physiological needs.
  • 3F Biofragrance: For mosquito avoidance and antimicrobial protection with confirmed in vitro effectiveness against MRSA, E.coli, Tuberculosis and SARS-CoV-2 (COVID-19). This technology is a surface disinfectant and is also designed to be incorporated into the Open Air Defense Initiative for protection against outbreaks by protecting key points where the potential spread of pathogens occurs.
  • Equivir: A patented Over the Counter (OTC) medication successfully tested in vitro against Rhinovirus, Influenza, Cholera, SARS-CoV-2 (COVID-19) and in a Biosafety Level 4 facility, Ebola. Equivir/Nemovir is both a treatment and a prophylactic for COVID-19 and is moving to human clinical trials.
  • Quantum: The solution to the Patent Cliff accomplished by creating a new class of medicinal chemistry that uses advanced methods to increase the effectiveness and persistence of natural compounds and existing drugs. The safety attributes of the original molecules are maintained. Typically, drug discovery processes modify functional groups.
  • Bioplastics: Antimicrobial plastics for consumer products that control the spread of active pathogens such as SARS-CoV-2, Influenza, E. coli, Staph, and Rhinovirus, by exploiting key strategies found in the biological realm. These new plastics are specifically focused on solutions for common products such as cups, plates, utensils, plastic bags, and countertops. The first prototypes have completed antimicrobial resistance testing.

Having an Impact
Early in the development process, GRDG began a working relationship with Impact Biomedical, who partnered with GRDG and provided investment capital to support its research.

“We saw an excellent opportunity to partner with Daryl and his team to accomplish something that has the potential to have a direct impact on the lives of millions of people around the world,” said Frank. D. Heuszel, President and Director of Impact BioMedical, Inc. “The ability to analyze the problem and creatively see a solution that can be disseminated quickly and without a relatively long lead team is special.”

Going Pro
The next key partner in GRDG’s pursuit of innovation came in a partnership with ProPhase Labs, which proposes to turn Thompson’s research into real-life products.

“For us, the science has to make sense,” said ProPhase Executive Vice President and COO Alice Lioi. “Daryl has formulated products that performed well in pre-clinical trials and the fact that they are based on natural substances is a different approach that we believe can strengthen products in the human world.”

While Moore, Impact, and ProPhase have all played key roles in GRDG’s research and development, it has been Thompson who may be the revelation of the documentary.

“I have always enjoyed working behind the scenes, working alongside government entities, but outside the trappings of bureaucracy — that’s where the real innovation takes place,” said Thompson. “But the work we have done for the past five years could have such an impact on the world, we just had to tell this story. So that’s what we’re doing. Parts of this story may sound impossible — trust me, I sometimes shake my head at the things we’ve been able to create — but at the end of the day, it still rings true.”

Diamond Studios, an Emmy Award-winning production company from Tampa, Fla., will produce the documentary, which will begin filming in December 2022.

About Impact BioMedical, Inc.
Impact BioMedical, Inc. (“Impact BioMedical”) is a wholly owned subsidiary of DSS. Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno-related diseases. For more information on Impact BioMedical visit http://impbio.com/.

About DSS, Inc.
DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation.

For more information on DSS visit http://www.dssworld.com.

Investor Contact:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
[email protected]

Safe Harbor Disclosure
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company’s intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in our SEC filings, including, without limitation, our reports on Forms 8-K, 10-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

.

Leave a Reply

Your email address will not be published.

Back to top button